Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

(d) On August 2, 2021, upon the recommendation of its Nominating and Corporate


    Governance Committee, the Board of Directors (the "Board') of Neuronetics,
    Inc. (the "Company") appointed Megan Rosengarten as a director and member of
    the Board's Compensation Committee. The Board determined that Ms. Rosengarten
    qualifies as an independent director under the director independence
    standards set forth by the Securities and Exchange Commission and applicable
    NASDAQ Stock Market LLC rules. Ms. Rosengarten's term will expire at the 2022
    annual meeting of stockholders of the Company. The Company will enter into an
    indemnification agreement with Ms. Rosengarten in connection with her
    appointment to the Board, in substantially the same form as that entered into
    with the Company's other directors.

In connection with her appointment and as approved by the Board, Ms. Rosengarten will receive compensation as a non-employee director as described in the Company's proxy statement for the 2021 Annual Meeting of Stockholders. There are no arrangements or understandings between Ms. Rosengarten and any other person pursuant to which she was selected as a director. Ms. Rosengarten has no family relationship with any director or executive officer of the Company and she has no direct or indirect material interest in any transaction involving the Company required to be disclosed under Item 404(a) of Regulation S-K.

Item 7.01 Regulation FD Disclosure.

On August 5, 2021, the Company issued a press release announcing Ms. Rosengarten's appointment to the Board. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits:




Exhibit
Number       Description

99.1           Press Release, dated August 5, 2021 of Neuronetics, Inc.

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses